CDMO Experic and particle engineering specialist Flurry Powders have announced a partnership to offer development services for inhaled and nasal drug formulations that require specialized particle engineering and manufacturing. The companies cite potential opportunities for dry powder formulations of biologics and other difficult molecules and say that they will offer a package of services through to GMP manufacturing.
According to the announcement, “Experic operates the only GMP spray dryer configured to Flurry’s proprietary PSD‑1 specifications, which have demonstrated 15–20% increases in lung dose relative to conventional PSD‑1 scale dryers.”
Experic first announced plans for DPI development and manufacturing services at its Cranbury, NJ facility in 2018 and the company received a significant investment from inhaler filling specialist Harro Höfliger in 2022 for expansion of that facility. In May 2023, Experic announced the addition of a pilot-scale spray dray at the Cranbury site. The company also has a clinical trial supply facility in Ireland.
Experic CEO Matthew Mollan commented, “Partnering with Flurry Powders expands the solutions we offer developers advancing inhaled and nasal therapies. By integrating spray-drying innovation with GMP manufacturing, we enable clients to reduce risk, accelerate timelines, and bring high-performing powder-based products into the clinic,” said , CEO of Experic.
Flurry Powders CEO Andreas Boeckl said, “Experic’s spray-drying capabilities, aligned with our PSD-1 system, create a seamless bridge from R&D to clinical manufacturing. Together, we enable innovators to advance complex inhalation and nasal products with greater confidence and performance.”
Read the Experic and Flurry Powders press release
